DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Proleukin (Aldesleukin) - Current Clinical Trials

 
 



Proleukin Related Clinical Trials

Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients [Recruiting]

Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer [Recruiting]

Aldesleukin in Patients With Metastatic Renal Cell Carcinoma and Metastatic Melanoma [Completed]

Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery [Recruiting]

Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2) [Recruiting]

Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M... [Completed]

Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia [Completed]

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma [Terminated]

Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent [Recruiting]

Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases [Completed]

High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery [Recruiting]

Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [Recruiting]

Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney [Completed]

A Phase I Study of Subcutaneously Administered Proleukin (Aldesleukin) in HIV-Infected Patients [Completed]

Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma [Completed]

Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma [Completed]

A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis [Completed]

Therapeutic Autologous Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant [Terminated]

Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma [Terminated]

Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma [Terminated]

Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer [Terminated]

Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma [Active, not recruiting]

Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma [Completed]

Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma [Active, not recruiting]

Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer [Active, not recruiting]

IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma [Withdrawn]

Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma [Recruiting]

Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer [Terminated]

Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma [Active, not recruiting]

Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People [Completed]

Proleukin and Rapamune in Type 1 Diabetes [Completed]

Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer [Completed]

Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 [Completed]

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma [Completed]

Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma [Recruiting]

Adaptive Study of IL-2 Dose Frequency on Regulatory T Cells in Type 1 Diabetes [Recruiting]

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma [Recruiting]

The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma [Active, not recruiting]

Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma [Terminated]

Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca [Terminated]

IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma [Recruiting]

Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma [Recruiting]

Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides [Terminated]

Cytokine-induced Memory-like NK Cells in Patients With AML or MDS [Recruiting]

Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma [Terminated]

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers [Recruiting]

Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells [Terminated]

Subcutaneously Administered Aldesleukin ( Interleukin-2; IL-2 ) Therapy in HIV-Infected Patients [Completed]

IL-2 for Multi Drug Resistant Nephrotic Syndrome [Completed]

Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 [Recruiting]

Tumor Infiltrating Lymphocytes (TIL) Transduced With TGFbDNRII [Recruiting]

Treating Patients With Childhood Acute Myeloid Leukemia With Interleukin-2 [Recruiting]

Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer [Completed]

Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma [Terminated]

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive [Recruiting]

A Study to Evaluate the Effects of Giving Proleukin (rIL-2) to HIV-Positive Patients With CD4 Counts Greater Than 300 Cells/mm3 [Completed]

Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma [Terminated]

Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor [Active, not recruiting]

Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer [Completed]

Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer [Completed]

Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma. [Completed]

Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer [Completed]

Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments [Completed]

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive [Recruiting]

Busulfan, Etoposide, and Total-Body Irradiation Followed by Autologous Stem Cell Transplant and Aldesleukin in Treating Patients With Acute Myeloid Leukemia in First Remission [Active, not recruiting]

Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study) [Completed]

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma [Recruiting]

Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma [Completed]

Drosophila-generated CTL [Terminated]

Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma [Completed]

Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia [Terminated]

CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer [Recruiting]

Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma [Completed]

Biomarkers That Predict Response to High-Dose Aldesleukin in Patients With Metastatic Kidney Cancer or Metastatic Melanoma [Active, not recruiting]

Biological Therapy in Treating Women With Stage IV Breast Cancer [Completed]

Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers. [Terminated]

Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma [Completed]

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome [Completed]

Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma [Completed]

Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML [Terminated]

Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant [Terminated]

Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection [Completed]

T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers [Recruiting]

CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII [Recruiting]

Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma [Completed]

High Risk Neuroblastoma Study 1.7 of SIOP-Europe (SIOPEN) [Recruiting]

Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation [Active, not recruiting]

Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies [Recruiting]

Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors [Terminated]

Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma [Active, not recruiting]

Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies [Recruiting]

Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma [Completed]

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy [Recruiting]

Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3 [Completed]

A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone [Completed]

Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation [Not yet recruiting]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015